Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Health and Drug Alerts

Combination hormone replacement therapy and dementia

Eric Wooltorton
CMAJ July 22, 2003 169 (2) 133;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Observational studies have suggested that hormone replacement therapy (HRT) may reduce the risk of cognitive decline in post-menopausal women.1 However, results from the Women's Health Initiative Memory Study (WHIMS)2,3 recently prompted a letter to Canadian health care professionals from Wyeth Canada warning that combination HRT may increase a woman's risk of dementia.4

The trial: The WHIMS trial2 prospectively followed 4381 postmenopausal women over the age of 65 who did not have dementia at study entry. The women were randomly assigned to receive either 1 daily tablet of 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (n = 2229) or a matching placebo (n = 2303). The women were followed for 4.2 years on average, and the incidence of dementia and mild cognitive impairment was determined in both groups with the use of structured cognitive assessments. The absolute risk of dementia was low in both groups (1 in 222 of women in the HRT group and 1 in 455 of those taking placebo), but the relative risk of dementia was doubled for those taking HRT (hazards ratio [HR] 2.05, 95% confidence interval [CI] 1.21–3.48). Alzheimer's disease was the principal form of dementia. The increased risk began in the second year of use, was observed in all age groups (but highest among those over 75) and persisted throughout the study. In addition, the combination HRT did not appear to prevent mild cognitive impairment, which occurred at the same rate in both groups (HR 1.07, 95% CI 0.74–1.55).

In a separate WHIMS study3 with identical study groups (combination HRT v. placebo), participants were followed up with annual Mini-Mental State Examinations (MMSE), but there were no differences between the groups in overall cognitive function. However, more women in the HRT group than in the placebo group had clinically significant declines in MMSE scores (6.7% v. 4.8%, p = 0.008).

What to do: Age-standardized rates of dementia are higher among women than among men,5 a difference hypothesized to be due to postmenopausal estrogen decline.2 However, combination HRT not only fails to prevent dementia, but it may increase the risk of it. Using the absolute risks generated from the WHIMS trial, we can estimate that treating 434 women over the age of 65 with combination HRT for 1 year would cause 1 new case of dementia. This risk should be appropriately figured into one's informed consent discussion about combination HRT use. Because the average age of women in the WHIMS trial was 71, the applicability of these risks to women under the age of 65 is unknown. It is also unclear whether other routes of delivery (e.g., transdermal) or different doses would confer the same risks of dementia. The failure of combined HRT regimens to prevent cardiovascular events6,7 has led to speculation that the progestins in combination regimens may attenuate any potential benefit conferred by estrogen alone. Results from an arm of the WHIMS trial currently underway that involves women with a hysterectomy who are taking either estrogen alone or a placebo may help to end this controversy.2 In the meanwhile, when HRT is indicated, it appears wise to use the lowest effective dose of combination HRT, for limited rather than prolonged periods.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Humphries KH, Gill S. Risks and benefits of hormone replacement therapy: The evidence speaks. CMAJ 2003;168(8):1001-10.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-72.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Important safety information on estrogen plus progesterone [Dear Health Care Professional Letter]. Markham (ON): Wyeth Canada; 2003 May 28. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/premplus_e.html (accessed 2003 June 24).
  5. 5.↵
    Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ 1994;150(6):899-913.
    OpenUrlAbstract
  6. 6.↵
    Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Yusuf S, Anand S. Hormone replacement therapy: a time for pause [editorial]. CMAJ 2002;167 (4):357-9.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (2)
CMAJ
Vol. 169, Issue 2
22 Jul 2003
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combination hormone replacement therapy and dementia
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combination hormone replacement therapy and dementia
Eric Wooltorton
CMAJ Jul 2003, 169 (2) 133;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Combination hormone replacement therapy and dementia
Eric Wooltorton
CMAJ Jul 2003, 169 (2) 133;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Women's health (including abortion)
    • Dementia & Alzheimer disease

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire